tocilizumab,cevostamab
roche
['mmsm', 'tocilizumab', 'toci', 'cevostamab']
pre-treatment with single dose tocilizumab before giving first dose bispecific moab cevostamab to patients with myeloma. reduces risk of crs from 90% to 35%. no impact on efficacy. #ash22 #mmsm 
Professor of Medicine, Chief of Myeloma Division & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami. Tweets = mine